Postgraduate School of Radiodiagnostics, Università degli Studi di Milano, Milan, Italy.
Department of Diagnostic and Interventional Radiology, Fondazione IRCCS Cà Granda, Policlinico di Milano Ospedale Maggiore, Via Sforza 35, 20122 Milan, Italy.
Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231157193. doi: 10.1177/15330338231157193.
Breast cancer (BC) is the most frequently diagnosed malignancy among women. In the past two decades, new technologies and BC screening have led to the diagnosis of smaller and earlier-stage BC (ESBC). Therefore, percutaneous minimally invasive techniques (PMIT) were adopted to treat patients unfit for surgery, women who refuse it, or elderly patients with comorbidities that could make surgery a difficult and life-threatening treatment. The target of PMIT is small-size ESBC with the scope of obtaining similar efficacy as surgery. Minimally invasive treatments are convenient alternatives with promising effectiveness, lower morbidity, less cost, less scarring and pain, and more satisfying cosmetic results. Ablative techniques used in BC are cryoablation, radiofrequency ablation, microwave ablation, high-intensity focused ultrasound (US), and laser ablation. The aim of our study is to discuss the current status of percutaneous management of BC, evaluate the clinical outcomes of PMIT in BC, and analyze future perspectives regarding ablation therapy in BC.
乳腺癌(BC)是女性最常见的恶性肿瘤。在过去的二十年中,新技术和 BC 筛查导致了更小和早期阶段 BC(ESBC)的诊断。因此,采用经皮微创技术(PMIT)来治疗不适合手术的患者、拒绝手术的女性,或因合并症而使手术成为困难和危及生命的治疗的老年患者。PMIT 的目标是具有获得与手术相似疗效的小体积 ESBC。微创治疗是一种具有前景的有效替代方法,具有较低的发病率、较低的成本、较少的疤痕和疼痛,以及更令人满意的美容效果。BC 中使用的消融技术有冷冻消融、射频消融、微波消融、高强度聚焦超声(US)和激光消融。我们的研究目的是讨论 BC 的经皮管理现状,评估 PMIT 在 BC 中的临床效果,并分析 BC 中消融治疗的未来前景。